CST, 3817S, Phospho-VEGF Receptor 2 (Tyr1059) (D5A6) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying VEGFR1 (Tyr1053) phosphate/VEGFR2 (Tyr1059) phosphate/VEGFR3 (Tyr1068) phosphate. Validated for Western Blotting. Available in 2 sizes. Highly specific and rigorously validated in-house, Phospho-VEGF Receptor 2 (Tyr1059) (D5A6) Rabbit Monoclonal Antibody (CST #3817) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity Phospho-VEGF Receptor 2 (Tyr1059) (D5A6) Rabbit Monoclonal Antibody only detects endogenous levels of VEGFR2 proteins when phosphorylated at Tyr1059. Since VEGF receptors 1, 2 and 3 share identical sequences within the epitope region, this antibody can also detect VEGF receptors 1 and 3 when phosphorylated at corresponding tyrosine residues. Species Reactivity: Human, Mouse Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr1059 of human VEGF receptor 2. Background Vascular endothelial growth factor receptor 2 (VEGFR2, KDR, Flk-1) is a major receptor for VEGF-induced signaling in endothelial cells. Upon ligand binding, VEGFR2 undergoes autophosphorylation and becomes activated (1). Major autophosphorylation sites of VEGFR2 are located in the kinase insert domain (Tyr951/996) and in the tyrosine kinase catalytic domain (Tyr1054/1059) (2). Activation of the receptor leads to rapid recruitment of adaptor proteins, including Shc, GRB2, PI3 kinase, NCK, and the protein tyrosine phosphatases SHP-1 and SHP-2 (3). Phosphorylation at Tyr1212 provides a docking site for GRB2 binding and phospho-Tyr1175 binds the p85 subunit of PI3 kinase and PLCγ, as well as Shb (1,4,5). Signaling from VEGFR2 is necessary for the execution of VEGF-stimulated proliferation, chemotaxis and sprouting, as well as survival of cultured endothelial cells and angiogenesis (6-8). Alternate Names CD309; CHTD7; Feline McDonough Sarcoma (FMS)-like tyrosine kinase 4; Fetal liver kinase 1; fetal liver kinase-1; FLK-1; FLK1; FLT; FLT-1; FLT-4; FLT1; FLT4; FLT41; fms related receptor tyrosine kinase 1; fms related receptor tyrosine kinase 4; fms related tyrosine kinase 1; fms related tyrosine kinase 4; Fms-like tyrosine kinase 1; Fms-like tyrosine kinase 4; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor); fms-related tyrosine kinase 4; FRT; KDR; Kinase insert domain receptor; kinase insert domain receptor (a type III receptor tyrosine kinase); LMPH1A; LMPHM1; PCL; primary congenital lymphedema; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; soluble VEGFR3 variant 1; soluble VEGFR3 variant 2; soluble VEGFR3 variant 3; tyrosine kinase growth factor receptor; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; Tyrosine-protein kinase receptor FLT4; Vascular endothelial growth factor receptor 1; Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 3; Vascular permeability factor receptor; VEGF receptor-3; VEGFR; VEGFR-1; VEGFR-2; VEGFR-3; VEGFR1; VEGFR2; VEGFR3; VGFR1; VGFR2; VGFR3 Specification REACTIVITY: H M SENSITIVITY: Endogenous MW (kDa): 230 Source/Isotype: Rabbit IgG